Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2004.037929v1, 2004; 10.1373/clinchem.2004.037929
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.037929v1
50/10/1907    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saviranta, P.
Right arrow Articles by Geierstanger, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saviranta, P.
Right arrow Articles by Geierstanger, B. H.

Received on June 5, 2004
Accepted on July 28, 2004

Oak Ridge Conference

Evaluating Sandwich Immunoassays in Microarray Format in Terms of the Ambient Analyte Regime

Petri Saviranta 1, Ryan Okon 2, Achim Brinker 1, Masaki Warashina 1, Joerg Eppinger 1, Bernhard H. Geierstanger 2*

1 Protein Science Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA, and Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA
2 Protein Science Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA

* To whom correspondence should be addressed. E-mail: geierstanger{at}gnf.org.

Background: Conceptionally, antibody microarrays are simply multiplexed sandwich immunoassays in a miniaturized format. However, from the amounts of capture antibodies used, it is not apparent whether such assays are ambient analyte (1) or mass-sensing devices (2). We evaluated multiplexed microarray sandwich assays for 24 mouse serum proteins in these terms within the boundaries of our experimental setup and based on theoretical considerations of the law of mass action.

Methods: Capture antibodies for 24 mouse serum proteins were printed on planar microarray substrates. After incubation with mixtures of purified antigens for 1 or 18 h, mixtures of biotinylated detection antibodies were used. High assay sensitivity was achieved by use of resonance-light-scattering particles for signal generation. Titration curves were generated for assay volumes of 20, 40, and 80 µL, and detection limits were calculated and compared. The assays were modeled theoretically based on the amounts of capture antibodies and the assay volumes used.

Results: As predicted, experimental variations of the assay volume by up to fourfold did not appreciably affect detection. Even for the most sensitive assay, <2% of the analyte molecules present in the sample were captured and generated signal at the detection limit. However, increasing the sample incubation time from 1 to 18 h on average lowered the detection limit threefold.

Conclusions: In our experimental setup, all 24 sandwich microarray assays fulfill the criteria of the "ambient analyte" regime because depletion of analyte molecules from the assay volume is insignificant.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
A. Claudon, P. Vergnaud, C. Valverde, A. Mayr, U. Klause, and P. Garnero
New Automated Multiplex Assay for Bone Turnover Markers in Osteoporosis
Clin. Chem., September 1, 2008; 54(9): 1554 - 1563.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Kverka, J. Burianova, R. Lodinova-Zadnikova, I. Kocourkova, J. Cinova, L. Tuckova, and H. Tlaskalova-Hogenova
Cytokine Profiling in Human Colostrum and Milk by Protein Array
Clin. Chem., May 1, 2007; 53(5): 955 - 962.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
W. Kusnezow, Y. V. Syagailo, S. Ruffer, N. Baudenstiel, C. Gauer, J. D. Hoheisel, D. Wild, and I. Goychuk
Optimal Design of Microarray Immunoassays to Compensate for Kinetic Limitations: Theory and Experiment
Mol. Cell. Proteomics, September 1, 2006; 5(9): 1681 - 1696.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Sanchez-Carbayo
Antibody Arrays: Technical Considerations and Clinical Applications in Cancer
Clin. Chem., September 1, 2006; 52(9): 1651 - 1659.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
B. B. Haab
Antibody Arrays in Cancer Research
Mol. Cell. Proteomics, April 1, 2005; 4(4): 377 - 383.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
F. Y. H. Lin, M. Sabri, J. Alirezaie, D. Li, and P. M. Sherman
Development of a Nanoparticle-Labeled Microfluidic Immunoassay for Detection of Pathogenic Microorganisms
Clin. Vaccine Immunol., March 1, 2005; 12(3): 418 - 425.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the American Association for Clinical Chemistry.